OB-Exos inhibit osteosarcoma (OS) cell proliferation, promote mineralization, and upregulate osteogenic markers like osteonectin (ON), bone sialoprotein (BSP), RUNX2, and OPN while downregulating URG4 expression. Here, SPARC is linked to osteosarcoma.